Annovis Bio (ANVS) Return on Capital Employed (2020 - 2026)
Annovis Bio (ANVS) posted Return on Capital Employed of 705.25% for Q1 2026, down 267.9% sequentially from 191.7% in Q4 2025, and down 56395.0% YoY from N/an in Q1 2025.
Annovis Bio (ANVS) Return on Capital Employed (2020 - 2026) Analysis & Trends
Annovis Bio has reported Return on Capital Employed for 7 years, with the latest figure at 705.25% in Q1 2026.
- Quarterly Return on Capital Employed fell 56395.0% year-over-year to 705.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 705.25% (down 56395.0% YoY) and the FY2025 annual result came in at 214.12%, up 11204.0% from the prior year.
- Return on Capital Employed declined to 705.25% in Q1 2026 per ANVS's latest filing, from 191.7% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 37.94% in Q1 2022 and troughed at 1722.55% in Q2 2024.
- A 5-year average of 390.8% and a median of 171.58% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed plunged 156870 bps in 2024, then jumped 161124 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 88.36% in 2022, then slumped by 759 bps to 758.6% in 2023, then surged by 66 bps to 260.07% in 2024, then gained by 26 bps to 191.7% in 2025, then tumbled by 268 bps to 705.25% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 705.25%, 191.7%, and 171.58% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - | -387.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -705.25% |
| Dec 31, 2025 | -191.70% |
| Sep 30, 2025 | -171.58% |
| Jun 30, 2025 | -111.31% |
| Mar 31, 2025 | -141.30% |
| Dec 31, 2024 | -260.07% |
| Sep 30, 2024 | -704.73% |
| Jun 30, 2024 | -1,722.55% |
| Mar 31, 2024 | -1,035.20% |
| Dec 31, 2023 | -758.60% |
| Sep 30, 2023 | -327.24% |
| Jun 30, 2023 | -153.86% |
| Mar 31, 2023 | -119.13% |
| Dec 31, 2022 | -88.36% |
| Sep 30, 2022 | -65.61% |
| Jun 30, 2022 | -49.10% |
| Mar 31, 2022 | -37.94% |
| Dec 31, 2021 | -32.08% |
| Sep 30, 2021 | -22.18% |
| Jun 30, 2021 | -34.55% |